Paracetamol

Registered South African indications:

• Pain
• Fever

This product contains paracetamol which may be fatal in overdose. In the event of overdosage or suspected overdose and notwithstanding the fact that the person may be asymptomatic, the nearest doctor, hospital or Poison Centre must be contacted immediately.

Registered South African contraindications

• Hypersensitivity to the active ingredient or any of its excipients
• Severe renal function impairment (tab)
• Severe liver function impairment

Contraindications registered in other jurisdictions

• Hypersensitivity to the active ingredient or any of its excipients

South African recommendations

Caution in the following patient groups

• Mild to moderate renal impairment (tab)
• Renal impairment (fct, cap, eft)
• Mild to moderate hepatic impairment

Effervescent tablet and capsule

Dosages in excess

• Dosages in excess of those recommended may cause severe liver damage

Liver or kidney disease

• Patients suffering from liver or kidney disease should take paracetamol under medical supervision

Duration of use

• Should not be use continuously for more than 10 days without consulting a doctor

Doctor consultation

• Patient should consult a doctor if no relief is obtained from the recommended dosage

Storage

• Store in a safe place out of reach of children

Additional precautions for effervescent tablet

Excessive use

• Excessive and prolonged use of this medicine may be dangerous

Sorbitol/maltitol/lactitol intolerance

• Patients with the rare hereditary condition of sorbitol/maltitol/lactitol intolerance should not take paracetamol effervescent tablets

Effects on ability to drive and use machines

• Paracetamol effervescent tablets have no or negligible influence on the ability to drive and use machines

Film-coated tablet

Severe liver damage

• Dosages in excess of those recommended may cause severe liver damage

Doctor consultation

• Patient should consult a doctor or pharmacist if pain or fever persists or gets worse at the recommended dosage, or if new symptoms occur

Duration of use

• Patient should not use this product continuously without consulting a medical practitioner: Pain – for more than 7 days in adults (5 days for children); and fever – for more than 3 days

Liver disease

• Patients suffering from hepatitis or alcoholism or recovering from any form of liver disease should not take excessive quantities of paracetamol film-coated tablets

Renal caution

• Caution is recommended in patients with moderate renal failure and patients on dialysis, as plasma concentrations of paracetamol tablets and its conjugates are increased

Renal impairment and malnutrition

• Use with caution in renal impairment, chronic malnutrition, or dehydration

Severe cutaneous adverse reactions (SCARs)

• Severe cutaneous adverse reactions (SCARs) such as toxic epidermal necrolysis (TEN), Stevens–Johnson syndrome (SJS), acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS)/ drug-induced hypersensitivity syndrome (DIHS) and fixed drug eruption (FDE) have been reported in patients treated with paracetamol-containing medicines
• If a patient develops SCAR, treatment with paracetamol film-coated tablets must immediately be discontinued and appropriate treatment instituted

Tablet

Severe liver damage

• Dosages in excess of those recommended may cause severe liver damage

Consultation with a medical practitioner

• Patient should consult a medical practitioner if no relief is obtained from the recommended dosage

Duration of use

• Patient should not use continuously for more than 10 days without consulting a medical practitioner

Tartrazine

• Some paracetamol tablet formulations contains FD & C Yellow No. 5 (Tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of tartrazine sensitivity in the general population is currently thought to be low, it is frequently seen in patients who also have aspirin sensitivity

Use with other paracetamol-containing products

• Patient should not use with any other paracetamol-containing products

Headaches

• Patients should be advised to consult their medical practitioner if their headaches become persistent

Non-serious arthritis

• Patients should be advised to consult a medical practitioner if they suffer from non-serious arthritis and need to take painkillers every day

Glutathione depletion

• Caution should be exercised in patients with glutathione depleted states, as the use of paracetamol may increase the risk of metabolic acidosis

Glutathione depletion due to metabolic deficiencies

• Use with caution in patients with glutathione depletion due to metabolic deficiencies. If symptoms persist, medical advice must be sought

Severe cutaneous adverse reactions (SCARs)

• Severe cutaneous adverse reactions (SCARs) such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), acute generalised exanthematous pustulosis (AGEP), eosinophilia and systemic (DRESS)/Drug-induced hypersensitivity syndrome (DIHS) and fixed drug eruptions (FDE) have been reported in patients treated with paracetamol-containing medicines
• If a patient develops SCAR, treatment with paracetamol tablets must immediately be discontinued and appropriate treatment instituted

Effects on ability to drive and use machines

• None

Recommendations in other jurisdictions

Caution in the following patient groups

• Renal impairment
• Hepatic impairment

Capsule

Paediatric population

• Not recommended for children under the age of 10 years

Renal and hepatic impairment

• Care is advised in the administration of paracetamol to patients with severe renal or severe hepatic impairment
• The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease

Dosage

• Patients should not exceed the recommended dose and should not take with any other paracetamol-containing products

Consultation with a doctor

• If symptoms persist patient should consult doctor

Storage

• Keep out of the reach of children

High anion gap metabolic acidosis (HAGMA)

• Cases of high anion gap metabolic acidosis (HAGMA) due to pyroglutamic acidosis have been reported in patients with severe illness such as severe renal impairment and sepsis, or in patients with malnutrition or other sources of glutathione deficiency (e.g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin
• If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended
• The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors

Overdose

• Immediate medical advice should be sought in the event of an overdose, even if you feel well, because of the risk of delayed, serious liver damage

Excipients

• This medicinal product contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 'sodium-free'

Effects on ability to drive and use machines

• Paracetamol has no influence on the ability to drive and use machines

Effervescent tablet

Renal and hepatic impairment

• Care is advised in the administration of paracetamol to patients with severe renal or severe hepatic impairment and in those with non-cirrhotic alcoholic liver disease
• The hazards of overdose are greater in those with alcohol liver disease

Dosage

• Patients should not take more medicine than the label tells them. If symptoms persist patient should be advised to consult doctor

Skin reactions

• Patients should be advised that paracetamol may cause severe skin reactions. If a skin reaction such as skin reddening, blisters, or rash occurs, they should stop use and seek medical assistance right away

Excipients

• Each tablet contains approximately 315 mg of sodium. This sodium should be taken into account when prescribing for patients on a sodium restricted diet
• Each tablet contains approximately 102 mg of lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine

High anion gap metabolic acidosis (HAGMA)

• Cases of high anion gap metabolic acidosis (HAGMA) due to pyroglutamic acidosis have been reported in patients with severe illness such as severe renal impairment and sepsis, or in patients with malnutrition or other sources of glutathione deficiency (e.g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin
• If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended
• The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors

Effects on ability to drive and use machines

• None known

Film-coated tablet

Paracetamol

• Contains paracetamol. Do not use with any other paracetamol-containing products

Liver and kidney impairment

• Underlying liver disease increases the risk of paracetamol-related liver damage. Patients who have been diagnosed with liver or kidney impairment must seek medical advice before taking this medication

Dosage

• Patients should not exceed the stated dose

Headaches and non-serious arthritis

• Patients should be advised to consult their doctor if their headaches become persistent
• Patients should be advised to consult a doctor if they suffer from non-serious arthritis and need to take painkillers every day

High anion gap metabolic acidosis (HAGMA)

• Cases of high anion gap metabolic acidosis (HAGMA) due to pyroglutamic acidosis have been reported in patients with severe illness such as severe renal impairment and sepsis, or in patients with malnutrition or other sources of glutathione deficiency (e.g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin
• If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended
• The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as the underlying cause of HAGMA in patients with multiple risk factors
• Use with caution in patients with glutathione depletion due to metabolic deficiencies

Symptoms

• If symptoms persist, medical advice must be sought

Storage

• Keep out of the sight and reach of children

Effects on ability to drive and use machines

• None

Tablet

Paediatric population

• Not recommended for children under the age of 10 years

Liver and kidney impairment

• Care is advised in the administration of paracetamol to patients with severe renal or severe hepatic impairment. The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease

Dosage

• Patients should not exceed the recommended dose
• Patients should not take for more than 3 days without consulting a doctor
• Patients should not take with any other paracetamol-containing products

Symptoms

• If symptoms persist, patients should consult doctor

Storage

• Keep out of the reach of children

High anion gap metabolic acidosis (HAGMA)

• Cases of high anion gap metabolic acidosis (HAGMA) due to pyroglutamic acidosis have been reported in patients with severe illness such as severe renal impairment and sepsis, or in patients with malnutrition or other sources of glutathione deficiency (e.g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin
• If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended
• The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as the underlying cause of HAGMA in patients with multiple risk factors

Overdose

• Immediate medical advice should be sought in the event of an overdose, even if you feel well, because of the risk of delayed, serious liver damage

Forms avail. in SA and covered in this monograph: cap, eft, fct, tab 

South African registered indications and dosages

Symptomatic relief of mild to moderate pain
Symptomatic relief of fever

• Oral (tab): 500mg, every 3hrs OR 500-1000mg, every 4-6hrs; Max: 4000mg/24hrs

Relief of mild to moderate pain and fever such as headaches, toothache and pain associated with colds and flu

• Oral (fct): 500-1000mg, every 4-6hrs; Max: 4000mg/24hrs
• Oral (cap): 500-1000mg, every 3-4hrs if necessary; Max: 4000mg/24hrs
• Oral (eft): 1000mg, dissolved in at least half a tumbler of water up to 4 times daily as required; Max: 2000mg/24hrs

---

Do not exceed recommended dose

Paed. forms avail. in SA and covered in this monograph: cap, eft, fct, tab

Paed. dosages below include:

• South African Standard Treatment Guidelines indications and dosages
• South African registered indications and dosages

---

South African Standard Treatment Guidelines indications and dosages

• Click here for the Pain Control (Standard Treatment Guidelines And Essential Medicines List For South Africa, Hospital Level, Paediatrics, 2023 Edition)
• Click here for the Anaesthetics (Standard Treatment Guidelines And Essential Medicines List For South Africa, Hospital Level, Paediatrics, 2023 Edition)
• Click here for the Palliative Care (Standard Treatment Guidelines And Essential Medicines List For South Africa, Hospital Level, Paediatrics, 2023 Edition)

---

South African registered indications and dosages

Relief of mild to moderate pain and fever such as headaches, toothache and pain associated with colds and flu

Oral (eft)

• Younger than 6 years: Not suitable for children under 6 years of age
• Between 6 to 12 years: 250-500mg, dissolved in water, given no more frequently than every 4hrs; Max: 2000mg/24hrs

Oral (fct)

• Younger than 6 years: Not recommended
• Between 6 to 12 years: 250-500mg, every 6hrs; Max: 2000mg/24hrs
• 12 years and older: 500mg, every 4-6hrs; Max: 2000mg/24hrs

---

Children should not be given doses of paracetamol effervescent tablets more frequently than every 4 hours and not more than 4 doses should be given in any 24 hour period
Children should not be given paracetamol effervescent tablets for more than 3 days without consulting a doctor

---

Symptomatic relief of mild to moderate pain
Symptomatic relief of fever

Oral (tab)

• Younger than 6 years: Not suitable for children under 6 years of age
• Between 6-12 years: Oral (tab): 250-500mg, three to four times a day as required

Relief of mild to moderate pain and fever such as headaches, toothache and pain associated with colds and flu

Oral (cap)

• Younger than 9 years: Not recommended
• Between 9-12 years: 500mg, every 3-4hrs if necessary; Max: 2000mg/24hrs

---

Do not exceed recommended dose

---

For other formulations see Paracetamol (SUS/SYR/DRP/SOL)

Pregnancy

• Safe
• Epidemiological studies in human pregnancy have shown no ill effects due to paracetamol used in the recommended dosage. A large amount of data on pregnant women indicate neither malformative, nor feto/neonatal toxicity
• When given to the mother in therapeutic doses (1g single dose), paracetamol crosses the placenta into foetal circulation as early as 30 minutes after ingestion and is metabolised in the foetus by conjugation with sulfate and increasingly with glutathione
• Paracetamol can be used during pregnancy if clinically needed however it should be used at the lowest effective dose for the shortest possible time and at the lowest possible frequency

Breastfeeding

• Compatible
• Paracetamol is excreted in breast milk but not in a clinically significant amount. Available published data do not contraindicate breastfeeding

Fertility

• There is no information relating to the effects of paracetamol on fertility

South African recommendations

Tablet

• Mild to moderate: Caution; no information available
• Severe: Contraindicated

Film-coated tablet

• Caution; no dose adjustment recommended
  Caution is recommended in patients with moderate renal failure and patients on dialysis, as plasma concentrations of paracetamol and its conjugates are increased
  Use with caution in renal impairment

Capsule and effervescent tablet

• Caution; no dose adjustment recommended
  Patients suffering from kidney disease should take paracetamol under medical supervision

Recommendations in other jurisdictions

Capsule, tablet and effervescent tablet

• Mild to moderate: Caution; no information available
• Severe: Caution; no dose adjustment recommended
  Care is advised in the administration of paracetamol to patients with severe renal impairment

Film-coated tablet

• Caution; no dose adjustment recommended
  Patients who have been diagnosed with kidney impairment must seek medical advice before taking this medication

South African recommendations

Tablet

• Mild to moderate: Caution; no information available
• Severe: Contraindicated

Film-coated tablet, capsule and effervescent tablet

• Mild to moderate: Caution; no dose adjustment recommended
  Patients suffering from liver disease should take paracetamol under medical supervision (cap, eft)
  Patients suffering from hepatitis or alcoholism or recovering from any form of liver disease should not take excessive quantities of paracetamol (fct)
• Severe: Contraindicated

Recommendations in other jurisdictions

• Caution; no dose adjustment recommended
  Care is advised in the administration of paracetamol to patients with severe hepatic impairment. The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease (fct, eft, cap)
  Underlying liver disease increases the risk or paracetamol related liver damage. Patients who have been diagnosed with liver impairment must seek medical advice before taking this medication (tab)

• No dose adjustment recommended

Respiratory Disorders

• Bronchospasm

Gastrointestinal Disorders 

• Acute pancreatitis

Hepatobiliary Disorders

• Hepatic impairment
• Liver injury (sus)
• Chronic hepatic necrosis (sus)
• Increased transaminases (sus)

Genitourinary Disorders

• Toxic nephropathy (sus)
• Renal papillary necrosis (sus)

Endocrine and Metabolic Disorders

• Acute pancreatitis

Skin and Subcutaneous Tissue Disorders

• Toxic Epidermal Necrolysis
• Steven-Johnson syndrome
• Acute generalised exanthematous pustulosis
• Fixed drug eruption
• Rash (sus)
• Rash pruritic (sus)
• Urticaria (sus)

Immune, Blood and Lymphatic System Disorders

• Hypersensitivity
• Anaphylactic shock
• Angioedema
• Stevens-Johnson syndrome
• Blood dyscrasias
• Thrombocytopenia
• Agranulocytosis

• Metoclopramide
• Domperidone
• Cholestyramine
• Oral anticoagulants
• Warfarin
• Chloramphenicol
• Anti-convulsants
• Carbamazepine (sus)
• Fosphenytoin (sus)
• Phenytoin (sus)
• Barbiturates
• Phenobarbital (sus)
• Primidone (sus)
• Alcohol
• Tricyclic antidepressants
• Oral contraceptives

None routine. Specific cases may require

• Hepatic function

The mechanism of analgesic action has not been fully determined. Paracetamol may act predominantly by inhibiting prostaglandin synthesis in the central nervous system (CNS) and, to a lesser extent, through a peripheral action by blocking pain impulse generation. The peripheral action may also be due to inhibition of prostaglandin synthesis or to inhibition of the synthesis or actions of other substances that sensitise pain receptors to mechanical or chemical stimulation. Paracetamol probably produces antipyresis by acting centrally on the hypothalamic heat regulating centre to produce peripheral vaso-dilation resulting in increased blood flow through the skin, sweating and heat loss. The central action probably involves inhibition of prostaglandin synthesis in the hypothalamus.

Tablet 500mg

• Actamol (Medicine Dev)
• Adco-Napamol (Adcock)
• Adco Prolief (Adcock)
• Antalgic  (Caps Pharmaceuticals)
• Austell-Paracetamol (Austell)
• Cetapon ( Resmed Healthcare)
• Codorol (Medicine Dev)
• Clicks Paracetamol (Ranbaxy Pharmaceuticals)
• Dis-Chem Paracetamol (Dischem)
• Dolorol (Pharmacare)
• Dynadol Tablets (Arya Pharma)
• Entalgic (Thebe)
• Gulf Paracetamol (Gulf Drug)
• Gencetamol (Alliance)
• JP Paracetamol (Gulf Drug)
• Pacimol (Austell)
• Panado (Adcock) originator
• Panado Spartan Pack (Adcock) originator
• Painamol (Ranbaxy)
• Painogesic (Innovata Pharmaceuticals)
• Painblok (Gulf Drug)
• Paracet (Be-tabs)
• Parapane (F.D.C SA)
• Pyngesic T (Cipla Medpro)
• Von Paracetamol (Gulf Drug)
• Varipan (LeBasi)
• Zydus Paracetamol (Zydus)
• Zypol (Unimed Healthcare)

Capsule 500mg

• Panado (Adcock) originator

Tablet effervescent 500mg

• Parafizz (Cipla)

Suspension (per 5ml) 120mg

• Calpol (Johnson & Johnson)

Syrup (per 5ml) 120mg

• Antalgic sf (Caps Pharmaceuticals)
• Adco-Napamol (Adcock)
• Adco-Paracetamol (Adcock)
• Barrs Paracetamol (Barrs Pharmaceuticals)
• Entalgic (Thebe)
• Feverpain (Medicine Developers)
• Go-Pain (Glenmark)
• Paracet (Be-tabs)
• Paracetamol Elixir Syrup (Pharmacare) Discontinued: 01/04/2018
• Paracetamol Red (Pharmacare)
• Panado paediatric alcohol and sugar free (Adcock) originator
• Panado paediatric strawberry (Adcock) originator
• Panado paediatric (Adcock) originator
• Painblok (Gulf Drug)
• Painamol (Ranbaxy)
• Pyngesic S (Cipla Medpro)
• Painogesic (Innovata Pharmaceuticals)
• Pyralen (Thebe)
• Woodward's Paracetamol (Pharmacare)

Caplets 650mg

• Tylenol Extended Relief (Johnson & Johnson)

Infant drops 60mg

• Panado (Adcock) originator

Also available in the following forms: injection and suppository.

COMBINATION PREPARATIONS

Aspirin/ Paracetamol/ Caffeine

Tablet 226.8mg/162mg/32.4mg

• Grand-pa (GSK)

Paracetamol/ Aspirin/ Caffeine

Tablet 100mg/400mg/30mg 

• Compral (Adcock)

Paracetamol/ Aspirin/ Caffeine

Powder 324mg/453.6mg/64.8mg

• Compral (Adcock)

Ibuprofen/ Paracetamol

Tablet 200mg/350mg

• Ibumol (Pharmacare)

Tablet 400mg/325mg

• Mypaid forte (Adcock) originator

Capsule 200mg/250mg 

• Ibupain (Sandoz SA)
• Dentopain (Sandoz SA)
• Mypaid  (Adcock) originator
• Panado Plus (Adcock)

Ibuprofen/ Paracetamol

Syrup (per 10ml) 200mg/250mg

• Ibumol (Pharmacare)
• Lotem (Adcock) originator

Codeine/ Paracetamol

Syrup (per 5ml) 5mg/120mg

• Infapain (Alliance) originator

Syrup (per 5ml) 4mg/150mg

• Supragesic (Innovata Pharmaceuticals)
• Tensopyn Paed syrup (Mirren)

Tablet 8mg/320mg

• Spectrapain (Akacia)

Tablet 8mg/500mg 

• Painamol plus (Be-Tabs)
• Paincodein (Innovata Pharmaceuticals)
• Vari-Cocodamol (LeBasi)
• Cogesic (Medicine Dev)
• Rocodin (Pharma Q)
• Dino-cod (Pharma Q)
• Dolorol forte (Pharmacare)

Tablet effervescent 8mg/500mg 

• Parafizz co  (Cipla)

Tablet 10mg/500mg 

• Kodapon (Gulf Drug) 

Paracetamol/ Mephenesin

Tablet 500/150mg 

• Spasmend (Adcock) originator

Paracetamol/ Doxylamine/ Caffeine/ Codeine

Tablet 450mg/5mg/30mg/10mg

• Abflex-4 (Cipla)
• Syndol  (Adcock) originator
• Tensopyn (Mirren)
• Resdol (Adcock)

Tablet 450mg/5mg/45mg/10mg

• Acurate (Pharmascript)
• Adco-dol (Adcock)
• Pynstop (Adcock )

Tablet  450mg/5mg/50mg/10mg

• Betapyn (Adcock)

Tablet effervescent 450mg/5mg/50mg/10mg

• Tensopyn (Mirren )

Tablet effervescent 450mg/5mg/30mg/10mg

• Doxy Co (Gulf Drug )
• Sedinol (Pharmacare)
• Sedapain (Pharmacare)
• Lenapain (Pharmacare)

Tablet effervescent 500mg/5mg/30mg/10mg

• Pharmadol (Medicine Developers)

Paracetamol/ Codeine/ Caffeine/ Phenyltoloxamine

Tablet 400mg/8mg/32mg/12mg

• Suncodin (Winthrop) originator

Codeine/ Meprobamate /Paracetamol

Capsule 8mg/200mg/400mg

• Synaleve (Adcock)
• Trinagesic (Adcock) originator

Tablet 10mg/125mg/500mg

• Meprogesic (Adcock) originator

Capsule 8mg/150mg/320mg 

• Stilpane (Pharmacare)

Codeine/ Promethazine/ Paracetamol

Syrup 5mg/6.5mg/120mg

• Lentogesic (Adcock)
• Goldgesic (Medicine Developers)

Orphenadrine/ Paracetamol

Tablet 35mg/450mg

• Betaflex NC (Adcock)
• Besemax (Adcock)
• Norflex Co (iNova) originator
• Uniflex (Adcock)

Tramadol/ Paracetamol

Tablet 37.5mg/325mg

• Tramacet (Janssen) originator
• Tramazac Co (Zydus)
• Tramahexal Co (Zydus)
• Ultracet (Janssen)

Paracetamol/ Codeine/ Caffeine/ Diphenhydramine

Tablet 400mg/10mg/50mg/5mg

• Lenadol (Pharmacare)
• Propain (Adcock)
• Tensolve (Pharmacare)

Paracetamol/ Codeine/ Diphenhydramine

Syrup (per 5ml) 150mg/4mg/10mg

• Meridol-D Paediatric Syrup (Medicine Dev)

Paracetamol/ Caffeine/ Codeine/ Meprobamate

Tablet 320mg/48mg/8mg/150mg

• Spectrapain forte (Akacia)
• Stopayne  (Adcock) originator

Paracetamol/ Caffeine/ Codeine/ Meprobamate

Tablet 320mg/32mg/8mg/150mg

• Adco-Payne (Adcock)
• Adco-Salterpyn (Adcock)
• Antipyn Forte (Pharmacare)
• Goldgesic (Medicine Dev)
• Go-Pain (Glenmark)
• Megapyn (Pharmacare)
• Nucopain (Gulf Drug)
• Pynmed (Cipla Medpro)
• Xergesic (Adcock) originator
• Hopyn (Innovata Pharmaceuticals)
• Stilpane (Pharmacare)

Paracetamol/ Codeine/ Meprobamate

Capsule 400mg/200mg/8mg 

• Synaleve (Adcock)
• Trinagesic (Adcock) originator

Tablet 500mg/125mg/10mg

• Meprogesic (Adcock) originator

Capsule 320mg/150mg/8mg 

• Stilpane (Pharmacare)

Paracetamol/ Codeine/ Ibuprofen

Capsule 250mg/10mg/200mg

• Dentopain Forte (Sandoz SA)
• Gen-Payne (Adcock)
• Ibupain Forte (Sandoz SA)
• Myprodol (Adcock) originator

Capsule 350mg/10mg/200mg

• Mybulen (Pharmacare)
• Mybucod (Pharmacare)

Suspension (per 10ml) 250mg/10mg/200mg

• Myprodol (Adcock) originator
• Mybulen (Pharmacare)